Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRL-1049 in Healthy Adult Participants
NCT07908134Phase 1Not yet recruiting
- Sponsor
- Neurelis
- Start
- Nov 2026
- Primary completion
- May 2027
01
Overview
Phase 1, randomised, double-blind trial of BA-1049 in cerebral cavernous malformation (CCM) (6 arms), sponsored by Neurelis. Primary endpoint: Treatment-emergent adverse events. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
BA-1049
03
Conditions
cerebral cavernous malformation (CCM)
Beyond the preview
Go deeper on NCT07908134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07908134.